PF-4708671

For research use only. Not for use in humans.

Licensed and Manufactured by Pfizer Catalog No.S2163

14 publications

PF-4708671 Chemical Structure

Molecular Weight(MW): 390.41

PF-4708671 is a cell-permeable inhibitor of p70 ribosomal S6 kinase (S6K1 isoform) with Ki/IC50 of 20 nM/160 nM in cell-free assays, 400-fold greater selectivity for S6K1 than S6K2, and 4- and >20-fold selectivity for S6K1 than MSK1 and RSK1/2, respectively. First S6K1-specific inhibitor to be reported.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 191 In stock
USD 147 In stock
USD 270 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's PF-4708671 has been cited by 14 publications

5 Customer Reviews

  • After treated with PF-4708671 (PF, 10 uM) and 4EGI-1 (50 uM) for 48 h, GRP78 and ATF4 in QBC939, RBE and HCCC-9810 cells were analyzed using western blot.

    PLoS One 2014 9(2), e90388. PF-4708671 purchased from Selleck.

  • (F) EGR-2 and GFI-1 abundance (n = 5).

    Front Immunol, 2017, 7:685. PF-4708671 purchased from Selleck.

  • Tumor sections were examined for DNA fragmentation (TUNEL) or stained with Ki-76 antibody. The representative images are shown. The brown color indicates the positively stained cells; scale bar, 50 mm.

    Mol Cancer Ther, 2015, 14(3): 799-809. PF-4708671 purchased from Selleck.

  • C. Cell lines were treated with the indicated compounds for 24h. ABC cells are colored in red. GCB are colored in blue. Intermediate cells are colored in gray.

    Oncotarget, 2016, 7(8):9163-74. PF-4708671 purchased from Selleck.

  • Effect of PF-4708671 on lipid accumulation and expression of lipogenic genes in HepG2 cells. Cells were exposed to 6 μM PF-4708671, 144 μM PA (sodium palmitate), or 14 nM RAPA (Rapamycin) for different periods of time. (b) The intracellular lipid content in each group was quantified. (c) Detection of TG levels.

    Nutr Metab (Lond), 2018, 15:31. PF-4708671 purchased from Selleck.

Purity & Quality Control

Choose Selective S6 Kinase Inhibitors

Biological Activity

Description PF-4708671 is a cell-permeable inhibitor of p70 ribosomal S6 kinase (S6K1 isoform) with Ki/IC50 of 20 nM/160 nM in cell-free assays, 400-fold greater selectivity for S6K1 than S6K2, and 4- and >20-fold selectivity for S6K1 than MSK1 and RSK1/2, respectively. First S6K1-specific inhibitor to be reported.
Targets
p70 S6K1 [1]
(Cell-free assay)
160 nM
In vitro

PF-4708671 is a piperazinyl-pyrimidine analogue and the first S6K1-specific inhibitor. PF-4708671 does not significantly inhibit the activity of the closely related S6K2 isoform or a number of other AGC kinases (Akt1, Akt2, PKA, PKCα, PKCϵ, PRK2, ROCK2, RSK1, RSK2 or SGK1) . PF-4708671 prevents the S6K1-mediated phosphorylation of S6 protein in response to IGF-1 (insulin-like growth factor 1), while having no effect upon the PMA-induced phosphorylation of substrates of the highly related RSK (p90 ribosomal S6 kinase) and MSK (mitogen- and stress-activated kinase) kinases. PF-4708671 is also found to induce phosphorylation of the T-loop and hydrophobic motif of S6K1, an effect that is dependent upon mTORC1 (mTOR complex 1). PF-4708671 does not affect activity of mTORC1. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
BHT-101 NFn1VJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7QcFRvUUN3ME2wMlgzODJ2IN88US=> MkDsV2FPT0WU
UACC-893 M{n3fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTVwMUm4PFYh|ryP MVrTRW5ITVJ?
A427 NGXYdldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jmdmlEPTB;NT63NlU3PyEQvF2= NX;2VII2W0GQR1XS
OCUB-M NHXvbIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\QTWM2OD14Lk[2NVAzKM7:TR?= NUTwPVdtW0GQR1XS
SW684 NFPmdmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTdwNUKyOlgh|ryP NVjKdIRCW0GQR1XS
SK-LMS-1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTlwMEGzNFIh|ryP M3rONHNCVkeHUh?=
CP50-MEL-B NInJOotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTlwM{C0NVkh|ryP M{P2VHNCVkeHUh?=
NCI-H1651 NWqxbo9rT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfqW3ZKSzVyPUGwMlAzPzZizszN NFPzSndUSU6JRWK=
ABC-1 NH;IVY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPZbmVxUUN3ME2xNE4yODN5IN88US=> NXfSTlhLW0GQR1XS
OE19 NH;SOYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nHdmlEPTB;MUCuNVc{OyEQvF2= NEDMV4xUSU6JRWK=
DSH1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NISyV4hKSzVyPUGwMlg5PzlizszN NGnhTmJUSU6JRWK=
SW13 NVXvPZhjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXXTWM2OD1zMT65N|E6KM7:TR?= MVjTRW5ITVJ?
MDA-MB-453 NHPnZ|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTF{LkG2NFMh|ryP NVjtUodvW0GQR1XS
647-V NHuwVHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo[3TWM2OD1zMj6zOVgzKM7:TR?= NUjP[Zo2W0GQR1XS
NCI-H2342 M3y5PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MknlTWM2OD1zMj6zPVk2KM7:TR?= M{HaPHNCVkeHUh?=
LB2241-RCC NXO3[VFqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1myWmlEPTB;MUKuOVc4QSEQvF2= M1\yc3NCVkeHUh?=
UACC-257 NVT1cJJQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWTPPFJGUUN3ME2xN{41PDV|IN88US=> MW\TRW5ITVJ?
NCI-H661 Mm\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTQTWM2OD1zMz62OFQ6KM7:TR?= MX;TRW5ITVJ?
FADU MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXHte4VOUUN3ME2xN{43QTl{IN88US=> MkfIV2FPT0WU
A2780 NUHKdpdsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPFS3FPUUN3ME2xN{45ODRzIN88US=> NEjiPYNUSU6JRWK=
NCI-H1793 M4HLfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkP0TWM2OD1zND60NFg2KM7:TR?= NVLFWGJIW0GQR1XS
TE-8 MlzuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGfoelVKSzVyPUG1MlM1PjVizszN MXTTRW5ITVJ?
HGC-27 M4HrZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTF4LkG2OFQh|ryP M3LUdHNCVkeHUh?=
MMAC-SF MnHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFfVZZpKSzVyPUG3MlM4OjdizszN Mmj0V2FPT0WU
Calu-6 NWnLWYFtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTF6LkG1NVMh|ryP MlfOV2FPT0WU
HUTU-80 NFP2dHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfyTIN2UUN3ME2xPE4{QTV7IN88US=> MXHTRW5ITVJ?
SAS NHHjPJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTFeolKSzVyPUG4MlY1PTVizszN M1\r[XNCVkeHUh?=
IST-MES1 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\uW2lEPTB;MUiuOlUxQCEQvF2= MV7TRW5ITVJ?
C3A NHvTOXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEDkSZRKSzVyPUG4Mlc6OTlizszN NFjQPJZUSU6JRWK=
ES3 M4Wwe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXpfIVKSzVyPUG4Mlg{PjRizszN M4LEPXNCVkeHUh?=
HSC-2 NVnNSopCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHQVlJKSzVyPUG5MlY2PDFizszN MmD1V2FPT0WU
T47D NWPhfJZ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjWZXJKSzVyPUKwMlE1QDVizszN MnjEV2FPT0WU
EW-7 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV3ZR3VEUUN3ME2yNE45PTh6IN88US=> NUDQXppDW0GQR1XS
LN-405 M37kVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkX1TWM2OD1{MD64PVY2KM7:TR?= NH7IRnpUSU6JRWK=
U031 M1fQe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXKTWM2OD1{MT60PFAzKM7:TR?= NViwTHdDW0GQR1XS
A549 NF3pb2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTJzLki0PVEh|ryP NIr4UodUSU6JRWK=
RMG-I MoLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPub483UUN3ME2yNk4zPjZ6IN88US=> M1XmbHNCVkeHUh?=
BT-474 NITJR3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTJ{Lk[1OVEh|ryP MWTTRW5ITVJ?
NB69 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTYTWM2OD1{Mz6xOVIh|ryP MXnTRW5ITVJ?
NB7 NFW4TlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmCxTWM2OD1{ND6xPFgh|ryP MUTTRW5ITVJ?
HCC1569 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTJ2Lk[xNlUh|ryP NFf1XFNUSU6JRWK=
MEL-JUSO MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;icJo5UUN3ME2yOE43QTB6IN88US=> NVTib5JIW0GQR1XS
MDA-MB-175-VII NY\DPVdIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVfjc2tWUUN3ME2yOU4zPTF5IN88US=> M1H0ZnNCVkeHUh?=
HCC1419 NIDyOG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLoTWM2OD1{NT62NFA{KM7:TR?= M3v5XnNCVkeHUh?=
Ca9-22 NHHYV2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPSTWM2OD1{NT62OFMzKM7:TR?= MmrSV2FPT0WU
KGN NWXDUGtkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfyfodKSzVyPUK1Mlc2PDdizszN MVPTRW5ITVJ?
LB373-MEL-D MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M33qOmlEPTB;Mk[uNVk{QCEQvF2= NELHSGVUSU6JRWK=
NCI-H1755 M1vIVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHwSnNHUUN3ME2yOk45QDRzIN88US=> NYTnPGZXW0GQR1XS
D-423MG MnHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\lSplMUUN3ME2yO{4xPzF3IN88US=> MWPTRW5ITVJ?
DK-MG NVfWd|d[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jMTGlEPTB;MkiuO|g1PiEQvF2= MUXTRW5ITVJ?
NCI-H1623 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTJ6LkizOFIh|ryP NGG0WGdUSU6JRWK=
KU-19-19 M4C5dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jPR2lEPTB;MkiuPVk2KM7:TR?= NYjScYdbW0GQR1XS
C-33-A MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXvJNJBLUUN3ME2yPU4zOTl6IN88US=> NWnsPYdxW0GQR1XS
SCC-4 M3LHd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYr5VYkzUUN3ME2zNE4{OzV2IN88US=> NIL0UHhUSU6JRWK=
MG-63 M2HGdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTNyLkW5PVQh|ryP M3uyTHNCVkeHUh?=
LNCaP-Clone-FGC NHPqPW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPKSoxKSzVyPUOxMlQ6OjFizszN NEPlZZRUSU6JRWK=
CAPAN-1 Mn:5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTNzLkWyPFYh|ryP NYXFO2o6W0GQR1XS
GI-ME-N M2fXWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTNzLkWzOVMh|ryP MoiwV2FPT0WU
RERF-LC-MS NHX1eFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmLvTWM2OD1|Mj62O|Q4KM7:TR?= MYnTRW5ITVJ?
KLE NInFRmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTN|LkSzN|Qh|ryP MkjxV2FPT0WU
KNS-81-FD NYPtWnNzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHDTWM2OD1|Mz61NFA5KM7:TR?= NILIOIxUSU6JRWK=
DOK NIjXXXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDsOmNKSzVyPUO0MlY3OTJizszN NV3iZY9lW0GQR1XS
ACHN MkLwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\RdGlEPTB;M{WuNVU5QCEQvF2= M2ezO3NCVkeHUh?=
KYSE-520 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTQNGxKSzVyPUO1MlI{PjFizszN MUnTRW5ITVJ?
SBC-5 MoK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{ftdmlEPTB;M{WuOVEyPiEQvF2= NH22eYxUSU6JRWK=
NCI-H28 M1\GW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37scmlEPTB;M{WuOlY6PSEQvF2= MlXTV2FPT0WU
ES7 NYDPN2ptT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnkV2VIUUN3ME2zOk4zOjR7IN88US=> NEnzPIZUSU6JRWK=
A172 NEG1NJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NILwO29KSzVyPUO2MlQyQDdizszN NHniXFBUSU6JRWK=
UM-UC-3 NIfRPFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;HZWlEPTB;M{euPFc1PiEQvF2= M2Dub3NCVkeHUh?=
LXF-289 M2q1R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{f5cmlEPTB;M{iuNFA1PyEQvF2= M4j4VHNCVkeHUh?=
KP-4 MnHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTN6LkS3N|kh|ryP MoLKV2FPT0WU
TE-1 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGDNeoZKSzVyPUO5MlY2QDlizszN MVnTRW5ITVJ?
G-402 M2nhemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTRyLkC2NUDPxE1? MV;TRW5ITVJ?
786-0 NEjsUJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NELNbVVKSzVyPUSwMlkxQTZizszN Mk\DV2FPT0WU
K5 Ml60S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nQUGlEPTB;NEGuN|Y5PiEQvF2= NHq1SnlUSU6JRWK=
SK-N-DZ NWTWVHhZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnnTWM2OD12MT6zPFI{KM7:TR?= M1PuW3NCVkeHUh?=
OVCAR-4 M3n2[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjLRlRSUUN3ME20NU44PTZ6IN88US=> NWf5e2FLW0GQR1XS
T84 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnD[YlKSzVyPUSyMlEzPjNizszN MYHTRW5ITVJ?
GCIY M1XuW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml3ETWM2OD12Mz6wPFA{KM7:TR?= MlzjV2FPT0WU
BB49-HNC NYXkOZl3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\uTWM2OD12Mz6zN|Q5KM7:TR?= MUjTRW5ITVJ?
SNU-C2B M{LSNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTR|Lk[0N|Yh|ryP NHzUfndUSU6JRWK=
TE-6 MmrZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HXU2lEPTB;NEOuPFg6PCEQvF2= M2TpfXNCVkeHUh?=
23132-87 NXjCXYM2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYfqZlVmUUN3ME20OE4zQTd6IN88US=> M3vySXNCVkeHUh?=
DMS-53 NVTxRZBOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1G5d2lEPTB;NESuN|M5PCEQvF2= NYG5OnpKW0GQR1XS
ONS-76 NXXicHpwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTR2Lke2OlEh|ryP MoXxV2FPT0WU
DMS-273 M1HYVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHaTWM2OD12ND65OFMh|ryP MV3TRW5ITVJ?
COLO-824 NHe1eWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1jOfWlEPTB;NEWuPFc4PSEQvF2= MWDTRW5ITVJ?
DMS-114 M2\tbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXf1WJVxUUN3ME20OU45QTJ5IN88US=> NVe5WIlUW0GQR1XS
YKG-1 Ml;lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HNWmlEPTB;NE[uNFM2PSEQvF2= NXTYSI9LW0GQR1XS
RH-18 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3L1NWlEPTB;NE[uN|c{OyEQvF2= Mm\SV2FPT0WU
NCI-H1355 Mn\qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFy2ZY9KSzVyPUS2MlYyQCEQvF2= M161fnNCVkeHUh?=
NCI-H2170 MnHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTR5Lke1PFQh|ryP MXrTRW5ITVJ?
OC-314 Mn7DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFvsSlRKSzVyPUS3Mlg1PzhizszN Mn3TV2FPT0WU
NCI-H2030 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDDTWM2OD12Nz64PVA3KM7:TR?= NF;h[HNUSU6JRWK=
22RV1 Mn\uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLjTWM2OD12Nz65NFE2KM7:TR?= NXnVT|Q4W0GQR1XS
G-401 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\0TWM2OD12OD60OFE2KM7:TR?= NG\YWGdUSU6JRWK=
YAPC MmLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3uTWM2OD12OT64NFc{KM7:TR?= NF7iNI9USU6JRWK=
SW1573 M{j4N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XhUGlEPTB;NUCuNlQ{PSEQvF2= M1qzUXNCVkeHUh?=
COLO-792 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWPBbnRJUUN3ME21NE43OjN5IN88US=> NWT3XnM6W0GQR1XS
KNS-62 M3LXemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\idmxbUUN3ME21NE44PTB6IN88US=> M2eyTHNCVkeHUh?=
NB5 MmKwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYjZc2xbUUN3ME21NU41PTB7IN88US=> M{\EXnNCVkeHUh?=
CP66-MEL NIPDdFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHETWM2OD13MT62OFA5KM7:TR?= MUDTRW5ITVJ?
CaR-1 Mo[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPsTWM2OD13Mj6wOlA3KM7:TR?= M3vXbXNCVkeHUh?=
CAL-54 MoPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHKyO5VKSzVyPUWyMlEyODJizszN MYPTRW5ITVJ?
8305C NH;3bIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV3j[lhRUUN3ME21Nk4{OTVizszN NGnXN5dUSU6JRWK=
Calu-3 Ml\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{PKVGlEPTB;NUKuN|c{OyEQvF2= NX3SNZVHW0GQR1XS
AU565 M{\ZN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXCXGs1UUN3ME21Nk42PTB7IN88US=> MnjSV2FPT0WU
CW-2 NX:xeGVNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFixOpZKSzVyPUWyMlg3PTRizszN MlfWV2FPT0WU
BEN MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITiSlVKSzVyPUWzMlc5PjJizszN M3rtN3NCVkeHUh?=
NCI-H1975 M{DtcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDrTWM2OD13Mz64PVY3KM7:TR?= M4rPOXNCVkeHUh?=
HCT-116 M4jJfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jLWWlEPTB;NUSuNFMzPyEQvF2= NX\BU2I2W0GQR1XS
SH-4 NWXKcFNUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXSTWM2OD13ND6xN|gh|ryP NWH1UI9[W0GQR1XS
NCI-H1693 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfRZmlKSzVyPUW0MlIyODNizszN NGPYTGdUSU6JRWK=
BPH-1 NV73Z3VMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYjublFNUUN3ME21OU4zQDl{IN88US=> NGiyd3VUSU6JRWK=
CAMA-1 NXy1WFc3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;GTWM2OD13NT64NVE3KM7:TR?= NV7xfYU{W0GQR1XS
A388 MoXTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPmfnlqUUN3ME21Ok4xQTh3IN88US=> NX\XfVZJW0GQR1XS
C2BBe1 NX[0NJk4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTV4LkK2N|Qh|ryP MnLFV2FPT0WU
GAMG MoDZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTJTWM2OD13Nj61PVU2KM7:TR?= MUjTRW5ITVJ?
MKN28 M1nMT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTV4LkiwNVMh|ryP M3fjenNCVkeHUh?=
VA-ES-BJ MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYCwVXF2UUN3ME21Ok45PzR3IN88US=> MXLTRW5ITVJ?
HuCCT1 NIXqTG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXRXo5KSzVyPUW3MlA1QTJizszN NFq4RW5USU6JRWK=
BFTC-905 M4raOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjDRXJKSzVyPUW3MlI5QThizszN M3r2R3NCVkeHUh?=
LS-123 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoOwTWM2OD13Nz61OlY5KM7:TR?= M2\MZ3NCVkeHUh?=
LB996-RCC NWS4doV3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV[zW2NoUUN3ME21PE4xOjh5IN88US=> NG\vSYdUSU6JRWK=
NCI-H1048 M4rwc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlL6TWM2OD13OD6yNVg5KM7:TR?= NIDBeHZUSU6JRWK=
COR-L105 M13ZNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4W1bWlEPTB;NUiuO|M{PyEQvF2= MnH1V2FPT0WU
OVCAR-8 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTV7LkG3NVYh|ryP M3e3TXNCVkeHUh?=
SK-N-FI MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXrkc3JFUUN3ME21PU4{OjB5IN88US=> NFGzSpZUSU6JRWK=
MES-SA NFTGUopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\vTWM2OD13OT60OVA6KM7:TR?= NYLPN2JvW0GQR1XS
SCC-9 M4Tocmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfs[5BKSzVyPUW5MlQ4PTNizszN NELuS2pUSU6JRWK=
EFO-27 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVvOVlBFUUN3ME21PU46PDNizszN Mnj0V2FPT0WU
GT3TKB NE\Ze5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYW5VoRWUUN3ME22NE43ODR6IN88US=> MkTvV2FPT0WU
HCC38 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGXpWolKSzVyPU[xMlQ{PzlizszN NHPnVpVUSU6JRWK=
MLMA NUOzc|k3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXvOHRKSzVyPU[xMlYyPjNizszN NUPWW|EzW0GQR1XS
D-566MG NVfUTGxOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTZ|LkWyNlQh|ryP M1;1enNCVkeHUh?=
SF295 NIHRTpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHzibJpKSzVyPU[zMlY3PTVizszN MljiV2FPT0WU
ES4 NH;nVppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLyenk5UUN3ME22OE41PzF7IN88US=> M1XzdnNCVkeHUh?=
CAKI-1 MofmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfkWIxKSzVyPU[0MlU4OjFizszN MX;TRW5ITVJ?
OAW-28 NUn3fJZ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3w[FdTUUN3ME22OE46PjR5IN88US=> NFX4dJRUSU6JRWK=
NCI-H460 MlG5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTZ3LkC4PVch|ryP NVnYbmNKW0GQR1XS
JAR NETwTJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7Ub2oxUUN3ME22OU42PTF4IN88US=> M{HscnNCVkeHUh?=
SNU-449 NFPiVpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFjPTVZKSzVyPU[1Mlc3OTZizszN MoLZV2FPT0WU
D-392MG MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEHHXVNKSzVyPU[1Mlk1OzRizszN NHjFWpJUSU6JRWK=
EW-22 NFexdZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTZ4LkO5OUDPxE1? NIW4N|hUSU6JRWK=
GCT NXLMXW5IT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTZ5LkC0OFMh|ryP MnTJV2FPT0WU
NOS-1 NF:0PIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3xTWM2OD14Nz62PFY4KM7:TR?= NFnNOVFUSU6JRWK=
RH-1 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;WR2JQUUN3ME22PE42PTV7IN88US=> MYfTRW5ITVJ?
HuH-7 MlTWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTZ7LkGwNFIh|ryP NG\iO5RUSU6JRWK=
NUGC-3 MoLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\RTWM2OD15MD65OlQ1KM7:TR?= MXfTRW5ITVJ?
IST-SL1 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnqTpVKSzVyPUexMlI{OjRizszN NUfQPJNDW0GQR1XS
SHP-77 M{XGSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvMZnFXUUN3ME23Nk4yOTlizszN NH3xV4VUSU6JRWK=
SW1116 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVy0SmJHUUN3ME23Nk4yPDB5IN88US=> M2fUcnNCVkeHUh?=
LK-2 M1HVVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{jB[2lEPTB;N{KuPFYyOiEQvF2= MmH5V2FPT0WU
U-2-OS NGXzWXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DKRmlEPTB;N{OuNVgzQCEQvF2= MlnVV2FPT0WU
KYSE-150 NHS0SYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3qPZNKSzVyPUezMlYyOThizszN MlXPV2FPT0WU
U251 NFnxRnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXvTWM2OD15Mz64NVY5KM7:TR?= MUjTRW5ITVJ?
HT-1080 NGHtZWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmTZTWM2OD15ND6yOVc1KM7:TR?= MYfTRW5ITVJ?
NCI-H1437 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTd2Lk[zNlYh|ryP M1;MSHNCVkeHUh?=
HPAF-II NXXaNpBkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmT1TWM2OD15ND62OFE2KM7:TR?= MX3TRW5ITVJ?
Becker M{DT[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXJO|JKSzVyPUe1MlEyODVizszN MVzTRW5ITVJ?
PANC-10-05 NFPrR4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTd3LkK4OlUh|ryP MlmwV2FPT0WU
TYK-nu NYDUZXZxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\GZYdxUUN3ME23OU4{OTB{IN88US=> MWPTRW5ITVJ?
SKG-IIIa MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NELYNZBKSzVyPUe1MlM{PDFizszN NFHCOYpUSU6JRWK=
NCI-H1993 NILKUXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmGzTWM2OD15NT63N|k4KM7:TR?= MkD2V2FPT0WU
S-117 Ml3uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4i0U2lEPTB;N{WuO|U2KM7:TR?= MWLTRW5ITVJ?
HuO9 NF25fotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\STWM2OD15Nj6wNFQ5KM7:TR?= NX64UoRUW0GQR1XS
CAL-51 M1rFc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFrSSmtKSzVyPUe2MlExODZizszN MnnnV2FPT0WU
BT-20 M4KyS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPWZnkxUUN3ME23Ok4zOTZ6IN88US=> M3zIUXNCVkeHUh?=
LB831-BLC NGrXcYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTd4LkOyNVch|ryP M3TO[nNCVkeHUh?=
LB1047-RCC M124NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\kTWM2OD15Nj63OlE6KM7:TR?= MYHTRW5ITVJ?
ES8 NFvqOVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3afVJKSzVyPUe4MlAxPzNizszN NFHtO5lUSU6JRWK=
UMC-11 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmK0TWM2OD15OD6wPFg1KM7:TR?= MXPTRW5ITVJ?
NCI-H226 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUTaPIZGUUN3ME23PE4yOzF3IN88US=> M3jmOXNCVkeHUh?=
IGROV-1 M1LkW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NETl[YZKSzVyPUe4MlU2PSEQvF2= NWHNUVF5W0GQR1XS
BHY MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVWz[49OUUN3ME23PU42QTZizszN MX;TRW5ITVJ?
MKN45 M2Xke2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmr4TWM2OD16MD6zNVc1KM7:TR?= NWW3ZWgxW0GQR1XS
IA-LM NEj6dGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjIPG9YUUN3ME24NE4{PTFzIN88US=> MnG1V2FPT0WU
WM-115 MmTUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2ruSmlEPTB;OEGuOFEyPCEQvF2= NF:2R5VUSU6JRWK=
VMRC-RCZ MmP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRThzLkS0NlUh|ryP MWXTRW5ITVJ?
NCI-H2291 NVm3ToxtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknjTWM2OD16MT62PFQzKM7:TR?= MX\TRW5ITVJ?
MCF7 M1vLd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYm4OZJQUUN3ME24N{4zQDl5IN88US=> MmnSV2FPT0WU
639-V NV\LfWQ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDmdoxKSzVyPUi0MlYyOjlizszN M134bHNCVkeHUh?=
RT4 NV63PGFOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVfaO|ZxUUN3ME24OU4zPDB|IN88US=> NULL[Ic4W0GQR1XS
NCI-H2405 NIrjdIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2TBT2lEPTB;OEWuNlk6PyEQvF2= M2LxSXNCVkeHUh?=
CAL-33 NHX4fGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfiTGREUUN3ME24OU43OzF3IN88US=> MYnTRW5ITVJ?
BT-549 NWrwTXN3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYDvOWdxUUN3ME24OU46Ozh{IN88US=> NIXOUItUSU6JRWK=
HT-1197 NWX5e3lVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnoTWM2OD16OD6xNFc4KM7:TR?= NVXDNHRnW0GQR1XS
G-361 NVzxT4s2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjwb|NKSzVyPUi4MlE1PzRizszN NIOwW5RUSU6JRWK=
LS-411N NV\hU2xlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPqXJJQUUN3ME24PU4{Ozh6IN88US=> NGnadYxUSU6JRWK=
HT-144 NV7afnJQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LFN2lEPTB;OEmuOVk6OiEQvF2= NHjHclJUSU6JRWK=
DJM-1 NFPZVpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTh7Lki4OFUh|ryP M4rzZXNCVkeHUh?=
CAL-12T MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXzdIQ5UUN3ME25NE44QDl3IN88US=> MYXTRW5ITVJ?
MKN7 MkiwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDhbWJDUUN3ME25NU4{PTVzIN88US=> M{\Je3NCVkeHUh?=
HuP-T3 NUj4XoV1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPEW4VKSzVyPUm2MlExODRizszN MXTTRW5ITVJ?
SK-MG-1 NXz5SnAyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{PoNmlEPTB;OU[uNVM1QCEQvF2= MoLpV2FPT0WU
NCI-H2347 NGTqe2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLiS21EUUN3ME25PE4yODR{IN88US=> NVPwRpF4W0GQR1XS
SW872 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFTJRXVKSzVyPUGwNE41PTZizszN NV3acoJ1W0GQR1XS
COLO-829 M3jBRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWX6Vll7UUN3ME2xNFAvPTV|IN88US=> NYOzNpg3W0GQR1XS
MC-IXC NV7OTphCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYS4b|RrUUN3ME2xNFAvPjF3IN88US=> MXnTRW5ITVJ?

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
pS6 / S6 / pS6K / S6K1 / pAKT / AKT ; 

PubMed: 28626016     


Western blot of cell lysates from neurons treated with PF-4708671, rapamycin, and Torin-2, individually or in combination for the indicated times.

p-mTOR / mTOR / p-p70S6K / p70S6K ; 

PubMed: 30423811     


As determined using Western blotting, the phospho-p70S6K (p-p70S6K) inhibitor (PF-4708671) reduced the expression of phospho-mTOR (p-mTOR) and p-p70S6K in SCC-4 and SCC-25 cells. SCC-4 and SCC-25 cells were not treated as negative control (NC) or treated with 20 µM PF-4708671 for 6 h (6 h), 12 h (12 h), 18 h (18 h), 1 day (1 d), 2 days (2 d), and 3 days (3 d). Western blot analysis was performed to examine the expression levels of p-mTOR, mTOR, p-p70S6K, p70S6K, and β-actin.

28626016 30423811
Growth inhibition assay
Cell viability; 

PubMed: 30423811     


Inhibitory effects of various doses (0.5, 1, 2, 5, 10, 20, and 40 µM) of PF-4708671 on SCC-4 (B) and SCC-25 (C) cells were assessed using MTT assay after 72 h of treatment. Data presented are the mean and standard error of the mean of three independent experiments. * p < 0.05, ** p < 0.01, and *** p < 0.001 indicate the statistical significance of differences between cells with and without treatment. t (red ** and *** for SCC-4 and blue *, ** and *** for SCC-25).

30423811

Protocol

Solubility (25°C)

In vitro DMSO 30 mg/mL (76.84 mM)
Ethanol 8 mg/mL (20.49 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
30% PEG400+0.5% Tween80+5% propylene glycol
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 390.41
Formula

C19H21F3N6

CAS No. 1255517-76-0
Storage powder
in solvent
Synonyms N/A
Smiles CCC1=CN=CN=C1N2CCN(CC2)CC3=NC4=C([NH]3)C=CC(=C4)C(F)(F)F

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Whether the in vivo formula "30% PEG400+0.5% Tween80+5% Propylene glycol" for S2163 is suitable for i.p. or not?

  • Answer:

    The formula "30% PEG400+0.5% Tween80+5% Propylene glycol" on our website is an oral one. It is a suspension.

S6 Kinase Signaling Pathway Map

Related S6 Kinase Products

Tags: buy PF-4708671 | PF-4708671 supplier | purchase PF-4708671 | PF-4708671 cost | PF-4708671 manufacturer | order PF-4708671 | PF-4708671 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID